AVY three-lens brief
Evidence-based stock research on AVY. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $201.80 — 20% above current (10 analysts).
AVY closed at $168.77 (-0.60%) as of 2026-09-11. Market cap: $12.91B. P/E (trailing) 18.6. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $201.80 — 20% above current (10 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $2.46B, net income $204.10M, free cash flow $1.00B.
Why three lenses on AVY, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AVYacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AVY" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AVY brief"></iframe>